Abstract:T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating lymphocytes is a predictor of favorable patient prognosis for many indications and is a requirement for responsiveness to immune checkpoint blockade therapy targeting programmed cell death 1. For tumors lacking immune infiltrate, or for which antigen processing and/or presentation has been downregulated, a promising immunotherapeutic approach is chimeric antigen receptor (CAR) T-cell therapy. CARs are hybrid receptors that link the tumor antigen specificity and affinity of an antibody-derived single-chain variable fragment with signaling endodomains associated with T-cell activation. CAR therapy targeting CD19 has yielded extraordinary clinical responses against some hematological tumors. Solid tumors, however, remain an important challenge to CAR T-cells due to issues of homing, tumor vasculature and stromal barriers, and a range of obstacles in the tumor bed. Protumoral immune infiltrate including T regulatory cells and myeloid-derived suppressor cells have been well characterized for their ability to upregulate inhibitory receptors and molecules that hinder effector T-cells. A critical role for metabolic barriers in the tumor microenvironment (TME) is emerging. High glucose consumption and competition for key amino acids by tumor cells can leave T-cells with insufficient energy and biosynthetic precursors to support activities such as cytokine secretion and lead to a phenotypic state of anergy or exhaustion. CAR T-cell expansion protocols that promote a less differentiated phenotype, combined with optimal receptor design and coengineering strategies, along with immunomodulatory therapies that also promote endogenous immunity, offer great promise in surmounting immunometabolic barriers in the TME and curing solid tumors.

Applying metabolic control strategies to engineered T cell cancer therapies

Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel

Metabolic challenges and interventions in CAR T cell therapy

Remodeling Metabolic Fitness: Strategies for Improving the Efficacy of Chimeric Antigen Receptor T Cell Therapy

Altered cancer metabolism and implications for next-generation CAR T-cell therapies

Targeting metabolism to improve CAR-T cells therapeutic efficacy

Metabolic engineering for optimized CAR-T cell therapy

Metabolic dialogues: regulators of chimeric antigen receptor T cell function in the tumor microenvironment

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Cutting-Edge CAR Engineering: Beyond T Cells

Optimising CAR T therapy for the treatment of solid tumors

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Tuning CAR T-cell therapies for efficacy and reduced toxicity